Effects of the CABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder

Pharmacopsychiatry

Volumn 42, Issue 6, 2009, Pages 266-269

  Zwanzger, P ^a   Eser, D ^b   Nothdurfter, C ^b   Baghai, T C ^b   Moller H J ^b   Padberg, F ^b   Rupprecht, R ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; TETRAGASTRIN; TIAGABINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANXIOLYTIC AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR; NIPECOTIC ACID DERIVATIVE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEART RATE; HUMAN; HYDROCORTISONE RELEASE; MALE; NAUSEA; PANIC; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANQUILIZING ACTIVITY; VERTIGO; ADOLESCENT; HOSPITALIZATION; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANXIETY; DOUBLE-BLIND METHOD; FEMALE; GABA AGONISTS; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS; PANIC; PANIC DISORDER; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70450257699     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1241798     Document Type: Article

References (27)

1. Ballenger JC, Burrows CD, DuPant Jr RL et al. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. I. Efficacy in short-term treatment. Archives of General Psychiatry 1988; 45: 413-422
2. Bandelaw B, Stein DJ, Dolberg OT et al. Improvement of quality of life in panic disorder with escitalopram, Citalopram, or placebo. Pharmacopsychiatry 2007; 40:152-156
3. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 10: 73-81
4. Bradwejn J. Koszycki D. Cholecystokinin and panic disorder: Past and future clinical research strategies Scandinavian Journal of Clinical and Laboratory Investigation, Supplement 2001 61 234 19-27 4 Bradwejn J, Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 2001; 19-27 (Pubitemid 33043622)
5. A-benzodiazepine binding sites in insular cortex of individuals with panic disorder Archives of General Psychiatry 2007 64 7 793-800 http://archpsyc.ama-assn.org/cgi/reprint/64/7/793 DOI 10.1001/archpsyc.64.7.793 5 Cameron OC, Huang CC, Nichols T et al. Reduced gamma-aminobutyric acid (A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Archives of General Psychiatry 2007; 64: 793-800 (Pubitemid 47026375)
6. Dillon DJ, Gorman JM, Liebowitz MR et al. Measurement of lactateinduced panic and anxiety. Psychiatry Res 1987; 20: 97-105
7. 1H-magnetic resonance spectroscopy Archives of General Psychiatry 2001 58 6 556-561 7 Coddard AW, Mason GF, Almai A et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Archives of General Psychiatry 2001; 58: 556-561 (Pubitemid 32523735)
8. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55
9. Hosler G, Nugent AC, Carlson PJ et al. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 2008; 65: 1166-1175
10. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 (Suppl 6): S4-11
11. PistovcakovaJ, Dostalek M, Sulcova A et al. Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression. Pharmacopsychiatry 2008; 41: 54-59
12. Pollack MH, Roy-Byrne PP, Van AM et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study. Journal of Clinical Psychiatry 2005; 66: 1401-1408
13. Sayin U. Cengiz S. Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures Pharmacological Research 1993 28 4 325-331 DOI 10.1006/phrs.1993.1134 13 Sayin U, Cengiz S, Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures. Pharmacology Research 1993; 28: 325-331 (Pubitemid 24027033)
14. Sayin U, Purali N, Ozkan T et al. Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacology Biochemistry and Behavior 1992; 43: 529-535
15. Schmitt U. Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze Behavioural Pharmacology 1999 10 2 131-137 15 Schmitt U, Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behavioral Pharmacology 1999; 10: 131-137 (Pubitemid 29150033)
16. Schmitt U, Luddens H, Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. Journal of Neural Transmission 2002; 109: 871-880
17. Sheehan DV, Sheehan KH, Raj BA et al. Psychopharmacol Bull. 2007; 40: 32-40
18. Sheriff, Harro J, el-Hwuegi A et al. Anxiolytic-like effect of the GABAtransaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity. Pharmacology Biochemistry and Behavior 1994; 49: 801-805
19. Sherif F, Oreland L. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Behavioral Brain Research 1995; 72: 135-140
20. Shlik J. Aluoja A. Vasar V. Vasar E. Podar T. Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder Journal of Psychiatry and Neuroscience 1997 22 5 332-340 20 Shlik J, Aluoja A, Vasar V et al. Effects of Citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997; 22: 332-340 (Pubitemid 28035937)
21. van Megen H, Westenberg HG, den Boer J et al. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK- 4 induced panic attacks. Psychopharmacology 1997; 129: 357-364
22. Zwanzger P. Baghai T. Boerner R.J. Moller H.-J. Rupprecht R. Anxiolytic effects of vigabatrin in panic disorder [7] Journal of Clinical Psychopharmacology 2001 21 5 539-540 DOI 10.1097/00004714-200110000-00017 22 Zwanzger P, Baghai T, Boerner RJ et al. Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 2001; 21: 539-540 (Pubitemid 32937442)
23. Zwanzger P. Baghai T.C. Schuele C. Strohle A. Padberg F. Kathmann N. Schwarz M. Moller H.-J. Rupprecht R. Vigabatrin decreases cholecystokinin- tetrapeptide (CCK-4) induced panic in healthy volunteers Neuropsychopharmacology 2001 25 5 699-703 DOI 10.1016/S0893-133X(01)00266-4, PII S0893133X01002664 23 Zwanzger P, Baghai TC, Schuele C et al. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 2001; 25: 699-703 (Pubitemid 32995952)
24. Zwanzger P, Eser D, Aicher S et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary- adrenalaxis activity: A placebo-controlled study. Neuropsychopharmacology 2003; 28:979-984
25. Zwanzger P, Baghai TC, Schule C et al. Tiagabine improves panic and agoraphobia in panic disorder patients. Journal of Clinical Psychiatry 2001; 62: 656-657
26. Zwanzger P. Eser D. Padberg F. Baghai T.C. Schule C. Rotzer F. Ella R. Moller H.-J. Rupprecht R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers Depression and Anxiety 2003 18 3 140-143 DOI 10.1002/da.10099 26 Zwanzger P, Eser D, Padberg F et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depression and Anxiety 2003; 18: 140-143 (Pubitemid 37463278)
27. Zwanzger P. Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder Journal of Psychiatry and Neuroscience 2005 30 3 167-175 27 Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. Journal of Psychiatry and Neuroscience 2005; 30: 167-175 (Pubitemid 40942455)